Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Stelara Settlement Places Firm Among Earlier US Rivals

Indian Biosimilars Giant Secures Early 2025 Launch Date For Ustekinumab

Executive Summary

Biocon Biologics has secured a launch date for its planned US biosimilar to Stelara that puts it ahead of some of the competition.

You may also be interested in...



Biocon And Eris Strike Indian Deal Over Branded Formulations

Biocon has announced a deal with fellow Indian pharma firm Eris Lifesciences that involves the sale of its local metabolics, oncology, and critical care products while also transferring its employees.

Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

As Biocon Biologics makes multiple moves to position its recently-integrated US biosimilars business for success, the firm’s chief commercial officer for advanced markets, Matt Erick, tells Generics Bulletin that US biosimilar competition is a “marathon” that is “not going to be won in the short term.”

‘We Are Going To Be Deeply Engaged In The Biosimilar Arena’ – Accord BioPharma Sets Out US Strategy

Hot on the heels of Accord BioPharma recently announcing a US filing for a Stelara biosimilar – as well as a settlement that will let it enter the market in May 2025 – Chrys Kokino, president of Accord US, talks about how the product fits into the firm’s wider biosimilars strategy in the first part of a two-part interview with Generics Bulletin.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel